Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents

Anti-Cancer Drug Design

Volumn 14, Issue 3, 1999, Pages 281-289

  Spicer, Julie A ^a   Gamage, Swarna A ^a   Atwell, Graham J ^a   Finlay, Graeme J ^a   Baguley, Bruce C ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Acridinecarboxamide; Anticancer drug; Intercalating agent; Phenazinecarboxamide

Indexed keywords

ACRIDINE DERIVATIVE; AMIDE; ANTINEOPLASTIC AGENT; CARBONYL DERIVATIVE; CYTOTOXIC AGENT; DIAMINE; DIMER; IMIDAZOLE DERIVATIVE; MITONAFIDE; PHENAZINE DERIVATIVE; TRICYCLIC AROMATIC COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CHEMICAL REACTION; CHROMATOPHORE; COLON TUMOR; CONTROLLED STUDY; DIMERIZATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOICHIOMETRY;

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL DIVISION; COLONIC NEOPLASMS; DIMERIZATION; DRUG SCREENING ASSAYS, ANTITUMOR; GROWTH INHIBITORS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; INTERCALATING AGENTS; JURKAT CELLS; LEUKEMIA P388; MICE; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0032818317     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Atwell G.J., Rewcastle G.W., Baguley B.C., Denny W.A. (1987) Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Journal of Medicinal Chemistry, 30, 664.
2. Atwell G.J., Bos C.D., Baguley B.C., Denny W.A. (1988) Potential antitumor agents. 56. 'Minimal' DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides. Journal of Medicinal Chemistry, 31, 1048.
3. Baguley B.C., Denny W.A., Atwell G.J., Cain B.F. (1981) Potential antitumor agents. Part 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues. Journal of Medicinal Chemistry, 24, 520.
4. Baguley, B.C., Zhuang L, Marshall E.M. (1995) Experimental solid tumour activity of N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide. Cancer Chemotherapy and Pharmacology, 36, 244.
5. Barnum E.R., Hamilton C.S. (1942). 5-Amino-and 1-amino-benz[f]quinolines and derivatives. Journal of the American Chemical Society, 64, 540.
6. Brana M.F., Castellano J.M., Roldan C.M., Santos A., Vazquez D., Jimenez A. (1980) Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8-naphthalic acid. Cancer Chemotherapy, Pharmacology, 4, 61.
7. Brana M. F., Castellano J. M., Moran M., Perez de Vega M. J., Romerdahl C. R., Qian X. D., Bousquet P., Emling F., Schlick E., Keilhauer G. (1993) Bis-naphthalimides: a new class of antitumor agents. Anti-Cancer Drug Design, 8, 257.
8. Brana M.F., Castellano J.M., Moran M., Perez de Vega M.J., Perron D., Conlon D., Bousquet P.F., Romerdahl C.A., Robinson S.P. (1996) Bis-naphthalimides 3: synthesis and antitumor activity of N,N′-bis[2-(1,8-naphthalimido)-ethyl]alkanediamines. Anti-Cancer Drug Design, 11, 297.
9. Chaires J.B., Leng F.F., Przewloka T., Fokt I., Ling Y.H., Perez-Soler R., Priebe W. (1997) Structure-based design of a new bisintercalating anthracycline antibiotic. Journal of Medicinal Chemistry, 40, 261.
10. Clemo G.R., McIlwain H. (1935) Syntheses and molecular complexes in the phenazine series. Part II. Journal of the Chemical Society, 738.
11. Denny W.A. (1989) DNA-intercalating agents as antitumour drugs: prospects for future design. Anti-Cancer Drug Design, 4, 241.
12. Denny W.A., Atwell G.J., Baguley B.C., Wakelin L.P.G. (1985) Potential antitumor agents. Part 44. Synthesis and antitumor activity of new classes of diacridines. The importance of linker chain rigidity for DNA binding kinetics and biological activity. Journal of Medicinal Chemistry, 28, 1568.
13. Denny W.A., Baguley B.C., Rewcastle G.W. (1990a) Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of 'minimal' DNA-intercalating agent which may not act via topoisomerase II. Journal of Medicinal Chemistry, 33, 814.
14. Denny W.A., Turner P.M., Atwell G.J., Rewcastle G.W., Ferguson L.R. (1990b) Structure-activity relationships for the mutagenic activity of tricyclic intercalating agents in Salmonella typhimurium. Mutation Research, 232, 233.
15. Esnault C., Roques P.B., Jacquemin-Sablon A., Le Pecq J.-B. (1984) Effects of new antitumor bifunctional intercalators derived from 7H-pyridocarbazole on sensitive and resistant L110 cell lines. Cancer Research, 44, 4355.
16. Finlay G.J., Riou J.-F., Baguley B.C. (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. European Journal of Cancer, 32A, 708.
17. Goldin A., Vendetti M.M., McDonald J.S., Muggia F.M., Henney J.E., Devita V.T. (1981) Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. European Journal of Cancer, 17, 129.
18. Hartley J.A., Reszka K., Zuo E.T., Wilson W.D., Morgan A.R., Lown J.W. (1988) Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation and photosensitization. Molecular Pharmacology, 33, 265.
19. Hernandez L., Cholody W.M., Hudson E.A., Resau J.H., Pauly G., Michejda C.J. (1995) Mechanism of action of bisimidazoacridones, new drugs with potent, selective activity against colon cancer. Cancer Research, 55, 2338.
20. Houghton P.J., Cheshire P.J., Hallman J.C., Gross J.L., McRipley R.J., Sun J.H., Behrens C.H., Dexter D.L., Houghton J.A. (1994) Evaluation of a novel bis-naphthalimide anticancer agent, DMP-840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemotherapy Pharmacology, 33, 265.
21. Le Pecq J.-B., Dat-Xuong N., Gosse C., Paoletti C. (1974) A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Proceedings of the National Academy of Sciences, USA, 71, 5078.
22. Lorusso P., Demchik L., Dan M., Polin L., Gross J.L., Corbett T.H. (1995) Comparative efficacy of DMP 840 against mouse and human solid tumor models. Investigational New Drugs, 13, 195.
23. McRipley R.J., Burns-Horwitz P.E., Czerniak P.M., Diamond R.J., Diamond M.A., Miller J.L.D., Page F.J., Dexter D.L., Chen S.F. (1994) Efficacy of DMP 840: a novel bisnaphthalimide cytotoxic agent with human solid tumor xenograft selectivity. Cancer Research, 54, 159.
24. Marshall E.S., Finlay G.J., Matthews J.H.L., Shaw J.H.F., Nixon J., Baguley B.C. (1992) Microculture-based chemo-sensitivity testing: a feasibility study comparing freshly explanted melanoma cells with human melanoma cell lines. Journal of the National Cancer Institute, 84, 340.
25. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M. (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. Journal of the National Cancer Institute, 83, 757.
26. Muss H.B., Blessing J.A., Eddy G.L., McGehee R. (1992) Echinomycin (NSC-526417) in recurrent and metastatic squamous cell carcinoma of the cervix - a Phase II trial of the Gynecologic Oncology Group (GOG). Investigational New Drugs, 10, 25.
27. Palmer B.D., Rewcastle G.W., Baguley B.C., Denny W.A. (1988) Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of tricyclic carboxamides. Journal of Medicinal Chemistry, 31, 707.
28. Palmer B.D., Lee H.H., Baguley B.C., Denny W.A. (1992) Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides, a new class of weakly-binding DNA-intercalating agents. Journal of Medicinal Chemistry, 35, 258.
29. Rewcastle G.W., Denny W.A., Baguley B.C. (1987) Potential antitumor agents. 51. Synthesis and antitumor activity of phenazine-1-carboxamides. Journal of Medicinal Chemistry, 30, 843.
30. Schepartz S., Venditti J.M., Plowman J., Wolpert M.K. (1981) Report on the Program of the Division of Cancer Treatment, National Cancer Institute.
31. Segal-Bendirjian E., Coulaud D., Roques B.P., Le Pecq J.-B. (1988) Selective loss of mitochondrial DNA after treatment of cells with ditercalinium (NSC 335153), an antitumor bis-intercalating agent. Cancer Research, 48, 4982.
32. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer Institute, 82, 1107.
33. Wadler S., Tenteromano L., Cazenave L., Sparano J.A., Greenwald E.S., Rozenblit A., Kaleya R., Wiernik P.H. (1994) Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemotherapy Pharmacology, 34, 266.
34. Wakelin L.P.G. (1986) Polyfunctional DNA intercalating agents. Medicinal Research Reviews, 6, 276.
35. Wakelin L.P.G., Atwell G.J., Rewcastle G.W., Denny W.A. (1987) Relationships between DNA binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents. Journal of Medicinal Chemistry, 30, 855.
36. Walls L.P. (1934) Researches on the phenanthridine series. Part III. Meso-substituted derivatives. Journal of the Chemical Society, 104.
37. Wilkoff L.J., Dulmadge E., Chopra D.P. (1980) Viability of cultured Lewis lung cell populations exposed to β-retinoic acid (40753). Proceedings of the Society for Experimental Biology and Medicine, 163, 233.